(Q38345404)

2 September 2017

1 reference

title

Pemphigus vulgaris: an evidence-based treatment update (English)

1 reference

2 September 2017

1 reference

Pemphigus vulgaris

1 reference

Cathy Y Zhao

1

1 reference

2 September 2017

Dedee F Murrell

series ordinal

2

1 reference

2 September 2017

publication date

1 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

75

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

271-284

1 reference

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Pemphigus: a treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Reliability and convergent validity of two outcome instruments for pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

A single cycle of rituximab for the treatment of severe pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Durable remission of pemphigus with a fixed-dose rituximab protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Rituximab in severe pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0353-6

Pemphigus therapy with oral prednisolone regimens. A 5-year study

21 January 2018

1 reference

12 December 2020

Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study

1 reference

12 December 2020

Treatment of oral pemphigus vulgaris

1 reference

12 December 2020

Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus

1 reference

12 December 2020

Interventions for pemphigus vulgaris and pemphigus foliaceus

1 reference

12 December 2020

Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus

1 reference

12 December 2020

A pilot study of etanercept treatment for pemphigus vulgaris

1 reference

12 December 2020

Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up

1 reference

12 December 2020

Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris

1 reference

12 December 2020

Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial.

1 reference

12 December 2020

The efficacy of acyclovir in treatment of the pemphigus vulgaris

1 reference

12 December 2020

Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973.

1 reference

12 December 2020

Adjuvant Therapy of Pemphigus

1 reference

12 December 2020

10.1007/S40265-015-0353-6

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1047701980

0 references

1 reference